iSpecimen Inc. Interest Expense Nonoperating
iSpecimen Inc. (ISPC) reported Interest Expense Nonoperating of $1.95 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- iSpecimen Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.00, a 100.00% decline year-over-year.
- iSpecimen Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $2.00, a 99.97% decline year-over-year.
- iSpecimen Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $1.95K, a 56.42% decline year-over-year.
- iSpecimen Inc. interest expense nonoperating for fiscal 2025 was $1.95K, a 98.88% decline from fiscal 2024.
- iSpecimen Inc. interest expense nonoperating for fiscal 2024 was $173.77K, a 986.00% increase from fiscal 2023.
- iSpecimen Inc. interest expense nonoperating for fiscal 2023 was $16.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $3.00 derived: sum of 2 quarters · filed 2026-04-01 | $3.00 derived: sum of 3 quarters · filed 2026-08-14 | $1.95K 10-K · filed 2026-04-01 |
| 2025-09-30 | $2.00 10-Q · filed 2025-11-17 | $2.00 derived: sum of 2 quarters · filed 2026-08-14 | $1.95K 10-Q · filed 2025-11-17 | $159.42K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.95K 10-Q · filed 2026-08-14 | $159.41K derived: sum of 3 quarters · filed 2026-08-14 | $166.78K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.95K 10-Q · filed 2026-05-18 | $159.41K derived: sum of 2 quarters · filed 2026-05-18 | $166.78K derived: sum of 3 quarters · filed 2026-05-18 | $171.25K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $157.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $164.83K derived: sum of 2 quarters · filed 2026-04-01 | $169.31K derived: sum of 3 quarters · filed 2026-04-01 | $173.77K 10-K · filed 2026-04-01 |
| 2024-09-30 | $7.36K 10-Q · filed 2025-11-17 | $11.84K derived: sum of 2 quarters · filed 2025-11-17 | $16.30K 10-Q · filed 2025-11-17 | |
| 2024-06-30 | $4.47K 10-Q · filed 2025-08-14 | $8.94K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $4.46K 10-Q · filed 2025-05-19 | |||
| 2023-12-31 | $16.00K 10-K · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |